60 Degrees Pharmaceuticals, Inc. Common Stock
Compare this stock
SXTP Stock Report Card
$
16%
Performance
Score:
10/100
SXTP returned -82.63% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Profit
Score:
10/100
Out of the last 4 quarters, SXTP has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
38/100
SXTP has had a lower than average amount of volatility over the last 12 months giving it a score of 37 of 100.
60 Degrees Pharmaceuticals, Inc. Common Stock Summary
Nasdaq / SXTP
Healthcare
Biotechnology
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
SXTP scored poorly on our reportcard. Here are some similar companies and how they performed.
